Idenix Pharmaceuticals Announces Samatasvir (IDX719) Poster Presentations at the Asian Pacific Association for the Study of the

Idenix Pharmaceuticals Announces Samatasvir (IDX719) Poster Presentations at
the Asian Pacific Association for the Study of the Liver (APASL) Conference

CAMBRIDGE, Mass., June 6, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals,
Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral diseases, today
announced three poster presentations featuring clinical and preclinical data
for samatasvir (IDX719), Idenix's once-daily pan-genotypic NS5A inhibitor for
the treatment of hepatitis C virus (HCV) infection, at the Asian Pacific
Association for the Study of the Liver (APASL) Liver Week 2013, taking place
in Singapore, June 6-10, 2013. Idenix recently initiated a phase II clinical
trial (HELIX-1) evaluating an all-oral, direct-acting antiviral (DAA) HCV
combination regimen of samatasvir and simeprevir (TMC435), a once-daily
protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB.

The following abstracts will be presented in poster sessions during APASL
Liver Week 2013 in the Conference Exhibition Hall on Friday, June 7, 2013,
8:30am - 5:30pm SGT:

  *Abstract No. 2110: "Pharmacokinetics and Pharmacodynamics of IDX719, a
    Pan-Genotypic HCV NS5A Inhibitor, in Genotype 1, 2, 3 or 4 HCV-Infected
  *Abstract No. 2121: "Hepatitis C Virus NS5A Inhibitor IDX719 Demonstrates
    Potent, Pan-genotypic Activity in Preclinical and Clinical Studies."
  *Abstract No. 2127: "IDX719, a Pan-genotypic HCV NS5A Replication Complex
    Inhibitor, Is a Promising Candidate for HCV Combination DAA Treatment."


Samatasvir is an NS5A inhibitor with low picomolar, pan-genotypic antiviral
activity in vitro. To date, samatasvir has been safe and well-tolerated after
single and multiple doses of up to 150 mg in healthy volunteers for up to 14
days' duration and up to 100 mg in HCV-infected patients up to 3 days'
duration. There have been no treatment-emergent serious adverse events
reported in the program. Samatasvir has demonstrated potent pan-genotypic
antiviral activity in HCV-infected patients with mean maximal viral load
reductions up to approximately 4.0 log[10] IU/mL across HCV genotypes 1-4 in a
proof-of-concept, three-day monotherapy study.

The HELIX-1 trial is a 12-week, randomized, double-blind, parallel group study
evaluating the safety and tolerability of samatasvir and simeprevir in
addition to antiviral activity endpoints, with a target enrollment of 90
treatment-naïve, non-cirrhotic, genotype 1b or 4 HCV-infected patients. The
HELIX-1 trial is the first study in HCV-infected patients to commence under a
non-exclusive collaboration agreement signed with Janssen in January 2013. A
second trial (HELIX-2) of samatasvir, simeprevir and TMC647055, a once-daily
non-nucleoside polymerase inhibitor boosted with low-dose ritonavir being
developed by Janssen, is expected to initiate in the second half of 2013.


Hepatitis C virus is a common blood-borne pathogen infecting three to four
million people worldwide annually.The World Health Organization (WHO)
estimates that more than 170 million people worldwide are chronically infected
with HCV, representing a nearly 5-fold greater prevalence than human
immunodeficiency virus.


Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a
biopharmaceutical company engaged in the discovery and development of drugs
for the treatment of human viral diseases. Idenix's current focus is on the
treatment of patients with hepatitis C virus (HCV) infection. For further
information about Idenix, please refer to


This press release contains "forward-looking statements" for purposes of the
safe harbor provisions of The Private Securities Litigation Reform Act of
1995, including but not limited to the statements regarding the Company's
future business and financial performance. For this purpose, any statements
contained herein that are not statements of historical fact may be deemed
forward-looking statements. Without limiting the foregoing, the words
"expect," "plans," "anticipates," "intends," "will," and similar expressions
are also intended to identify forward-looking statements, as are expressed or
implied statements with respect to the Company's potential pipeline
candidates, including any expressed or implied statements regarding the
efficacy and safety of IDX719 or any other drug candidate; the successful
development of novel combinations of direct-acting antivirals for the
treatment of HCV; the likelihood and success of any future clinical trials
involving IDX719 or our other drug candidates; and expectations with respect
to funding of operations and future cash balances. Actual results may differ
materially from those indicated by such forward-looking statements as a result
of risks and uncertainties, including but not limited to the following: there
can be no guarantees that the Company will advance any clinical product
candidate or other component of its potential pipeline to the clinic, to the
regulatory process or to commercialization; management's expectations could be
affected by unexpected regulatory actions or delays; uncertainties relating
to, or unsuccessful results of, clinical trials, including additional data
relating to the ongoing clinical trials evaluating its product candidates; the
Company's ability to obtain additional funding required to conduct its
research, development and commercialization activities; changes in the
Company's business plan or objectives; the ability of the Company to attract
and retain qualified personnel; competition in general; and the Company's
ability to obtain, maintain and enforce patent and other intellectual property
protection for its product candidates and its discoveries. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause actual results to be materially different from
any future results, performance or achievements expressed or implied by such
statements. These and other risks which may impact management's expectations
are described in greater detail under the heading "Risk Factors" in the
Company's quarterly report on Form 10-Q for the quarter ended March 31, 2013
as filed with the Securities and Exchange Commission (SEC) and in any
subsequent periodic or current report that the Company files with the SEC.

All forward-looking statements reflect the Company's estimates only as of the
date of this release(unless another date is indicated) and should not be
relied upon as reflecting the Company's views, expectations or beliefs at any
date subsequent to the date of this release. While Idenix may elect to update
these forward-looking statements at some point in the future, it specifically
disclaims any obligation to do so, even if the Company's estimates change.

CONTACT: Idenix Pharmaceuticals Contact:
         Teri Dahlman, (617) 995-9807

Idenix Pharmaceuticals logo
Press spacebar to pause and continue. Press esc to stop.